Moshe Giladi - 27 Feb 2024 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role: Chief Science Officer
Signature: Steven Robbins, as attorney in fact for Giladi, Moshe
Issuer symbol: NVCR
Transactions as of: 27 Feb 2024
Net transactions value: +$2,107,557
Form type: 4
Filing time: 29 Feb 2024, 16:33:08 UTC
Previous filing: 20 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVCR	Ordinary Shares	Award	$833,321	+51,124	+274%	$16.30	69,771	27 Feb 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NVCR	Stock Options (Right to buy)	Award	$1,274,236	+78,174		$16.30	78,174	27 Feb 2024	Ordinary Shares	78,174	$16.30	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
F2	Options to buy 78,174 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.